March 6, 2018
Aurora Health Care has been named one of the first health care systems in the United States and the only in Wisconsin to participate in a precision medicine study of a new drug for the fight against colon cancer.
Aurora’s cancer and research programs are participating in the early-phase Mountaineer study, a clinical trial using precision-based therapy protocols and the new drug for advanced metastatic colon cancer tucatinib, which was developed by Cascadian Therapeutics
“Patients throughout Wisconsin turn to Aurora Health Care for the best in treatment options, and being a host for this study builds on our overall reputation as a destination for cancer care,” said Federico Sanchez, MD, medical director for oncology services at Aurora Cancer Care and the principal investigator for Aurora Research Institute. “We are always looking for better options for our patients, and we are hopeful that our participation in this study will lead to even better patient outcomes for future patients.”
Sponsored by Academic and Community Cancer Research United (ACCRU), the study will be available at 16 Aurora Cancer Care sites. Other systems participating in the study are some of the major cancer research organizations in the U.S., including Duke University, MD Anderson Cancer Center, Dana-Farber Cancer Institute and Mayo Clinic, the coordinating system for the study.
“An integrated health system, Aurora is able to offer this option to patients close to home at clinics throughout Eastern Wisconsin,” said Michael Thompson, MD, PhD, medical co-director of Oncology Precision Medicine for Aurora Cancer Care and director of Early Phase Cancer Research for Aurora Research Institute.
Colon cancer is the second leading cause of cancer-related deaths in the U.S., and American Cancer Society estimates that more than 95,000 people will be diagnosed this year.
To learn more about the clinical trial or options available to patients, visit aurora.org/research.